Innovation in bone healing and tissue repair
  • slidebg1
  • slidebg1
  • slidebg1
  • slidebg1
  • slidebg1
Kuros Biosciences AG is a Swiss-based company focused on the development of innovative products for tissue repair and regeneration.

Kuros has developed a pipeline of clinical and preclinical programmes at various stages of development and generated significant data in a number of indications and applications. The most advanced programmes are targeting commercially attractive opportunities in certain segments of the tissue repair and regeneration space, notably sealants and orthobiologics. In addition to many years of substantial preclinical work, Kuros Biosurgery has now enrolled over 600 patients in multi-national clinical trials, generating promising safety and efficacy in a number of indications.

Latest News
13 Apr 17
Kuros announces CEO succession
- Commercialization veteran and life science executive Dr. Ivan Cohen-Tanugi named Chief Executive Officer of Kuros - Didier Cowling will serve as President on the Executive Committee and remain on the Board of... READ MORE


27 Feb 17
Kuros receives clearance from the US FDA for MagnetOs allowing marketing in the United States
Kuros Biosciences (SIX: KURN) announces today that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for MagnetOs Granules. FDA’s approval clearance allows marketing in the United States indicated for use as an... READ MORE


Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kuros.ch

About Kuros

  1. Overview
  2. Management
  3. Board

Products

  1. Pipeline
  2. Orthobiologics
    Fracture repair
    KUR-111
    KUR-113
    MagnetOs
    Spinal fusion
    KUR-113
    MagnetOs
    Solitary Bone Cysts
    KUR-112
  3. Sealants
    Neuroseal (KUR-023)

Technologies

  1. Overview
  2. Surface Science Technology
  3. Synthetic Cross-Linking Technology
  4. Fibrin-Based
  5. Immune Modulation
  6. Publications

Partnerships

  1. Collaborations
  2. Business development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & presentations
  4. Calendar
  5. Corporate governance
  6. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Kuros Biosciences AG is a Swiss-based company focused on the development of innovative products for tissue repair and regeneration.

Kuros has developed a pipeline of clinical and preclinical programmes at various stages of development and generated significant data in a number of indications and applications. The most advanced programmes are targeting commercially attractive opportunities in certain segments of the tissue repair and regeneration space, notably sealants and orthobiologics. In addition to many years of substantial preclinical work, Kuros Biosurgery has now enrolled over 600 patients in multi-national clinical trials, generating promising safety and efficacy in a number of indications.

Latest News
13 Apr 17
Kuros announces CEO succession
- Commercialization veteran and life science executive Dr. Ivan Cohen-Tanugi named Chief Executive Officer of Kuros - Didier Cowling will serve as President on the Executive Committee and remain on the Board of... READ MORE


27 Feb 17
Kuros receives clearance from the US FDA for MagnetOs allowing marketing in the United States
Kuros Biosciences (SIX: KURN) announces today that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for MagnetOs Granules. FDA’s approval clearance allows marketing in the United States indicated for use as an... READ MORE